article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

This month’s announcement that Alphabet’s Isomorphic Labs, led by the talented and charismatic Deepmind co-founder Demis Hassabis, had inked discovery collaboration deals with both Lilly and Novartis was just the latest indication that AI-enabled pharma R&D was ready for the big time.

article thumbnail

AI Drug Discovery: Revolutionizing Pharma R&D with Artificial Intelligence

Crown Bioscience

Companies like Crown Bioscience are at the forefront, utilizing AI to compress the timeline for drug development from years to months. The impact is tangibleAI capabilities in predictive modeling and simulation are not only speeding up the process but also increasing the probability of discovering viable drug candidates.